Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical outcomes of synchronous head and neck and esophageal cancer

  • Park, Jae Won (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Sang-wook (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2015.05.15
  • Accepted : 2015.07.14
  • Published : 2015.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To investigate clinical outcomes of synchronous head and neck and esophageal cancer (SHNEC). Materials and Methods: We retrospectively reviewed 27 SHNEC patients treated with curative intent at a single institution. The treatment modality for individual cases was usually determined on a case by case basis. Results: The median follow-up duration for the surviving patients was 28.2 months. The most common site of head and neck cancer was hypopharyngeal carcinoma (n = 21, 77.7%). The lower esophagus was the most common location of esophageal carcinoma (n = 16, 59.3%). The 2-year progression-free survival (PFS) and overall survival (OS) rates were 57.5% and 39.6%. Major pattern of failure was locoregional recurrence in the study patients. Esophageal cancer stage, the Eastern Cooperative Oncology Group (ECOG) performance status, and pretreatment weight loss were significant prognostic factors for OS in univariate analysis. Treatment-related death was observed in two patients, and one patient developed a grade 4 late treatment-related complication. Conclusion: Although the survival outcome for SHNEC is poor, long-term survival might be achievable with aggressive treatment with stage I-II esophageal cancer and good performance.

Keywords

References

  1. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953;6:963-8. https://doi.org/10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q
  2. Strong MS, Incze J, Vaughan CW. Field cancerization in the aerodigestive tract: its etiology, manifestation, and significance. J Otolaryngol 1984;13:1-6.
  3. Lee GD, Kim YH, Kim JB, et al. Esophageal cancer associated with multiple primary cancers: surgical approaches and longterm survival. Ann Surg Oncol 2013;20:4260-6. https://doi.org/10.1245/s10434-013-3183-3
  4. Noguchi T, Kato T, Takeno S, Wada S, Yanagisawa S, Suzuki M. Necessity of screening for multiple primary cancers in patients with esophageal cancer. Ann Thorac Cardiovasc Surg 2002;8:336-42.
  5. Shirai K, Tamaki Y, Kitamoto Y, et al. Prognosis was not deteriorated by multiple primary cancers in esophageal cancer patients treated by radiotherapy. J Radiat Res 2013;54:706-11. https://doi.org/10.1093/jrr/rrt002
  6. Wang WL, Wang CP, Wang HP, et al. The benefit of pretreatment esophageal screening with image-enhanced endoscopy on the survival of patients with hypopharyngeal cancer. Oral Oncol 2013;49:808-13. https://doi.org/10.1016/j.oraloncology.2013.04.009
  7. Fukuzawa K, Noguchi Y, Yoshikawa T, et al. High incidence of synchronous cancer of the oral cavity and the upper gastrointestinal tract. Cancer Lett 1999;144:145-51. https://doi.org/10.1016/S0304-3835(99)00223-2
  8. Shaha AR, Hoover EL, Mitrani M, Marti JR, Krespi YP. Synchronicity, multicentricity, and metachronicity of head and neck cancer. Head Neck Surg 1988;10:225-8. https://doi.org/10.1002/j.1930-2398.1988.tb00003.x
  9. Muto M, Hironaka S, Nakane M, Boku N, Ohtsu A, Yoshida S. Association of multiple Lugol-voiding lesions with synchronous and metachronous esophageal squamous cell carcinoma in patients with head and neck cancer. Gastrointest Endosc 2002;56:517-21. https://doi.org/10.1016/S0016-5107(02)70436-7
  10. Katada C, Muto M, Nakayama M, et al. Risk of superficial squamous cell carcinoma developing in the head and neck region in patients with esophageal squamous cell carcinoma. Laryngoscope 2012;122:1291-6. https://doi.org/10.1002/lary.23249
  11. Miyazaki T, Sohda M, Higuchi T, et al. Effectiveness of FDG-PET in screening of synchronous cancer of other organs in patients with esophageal cancer. Anticancer Res 2014;34:283-7.
  12. Yoshino K, Endo M, Nara S, Ishikawa N. Surgery for synchronous double cancer in the hypopharynx and thoracic esophagus. Hepatogastroenterology 1995;42:275-8.
  13. Shinoto M, Shioyama Y, Sasaki T, et al. Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer. Am J Clin Oncol 2011;34:362-6. https://doi.org/10.1097/COC.0b013e3181e84b4b
  14. Wallach JB, Rosenstein MM, Kalnicki S. Localized synchronous squamous cell carcinomas of the esophagus and hypopharynx treated with definitive concurrent chemoradiotherapy with a unified radiotherapy plan. Curr Oncol 2014;21:e354-7. https://doi.org/10.3747/co.21.1844
  15. Welz S, Schmid A, Hehr T, et al. Treatment-outcome for synchronous head-and-neck and oesophageal squamous cell carcinoma. Radiother Oncol 2005;77:267-70. https://doi.org/10.1016/j.radonc.2005.07.004
  16. Wind P, Roullet MH, Quinaux D, Laccoureye O, Brasnu D, Cugnenc PH. Long-term results after esophagectomy for squamous cell carcinoma of the esophagus associated with head and neck cancer. Am J Surg 1999;178:251-5. https://doi.org/10.1016/S0002-9610(99)00163-4
  17. Di Fiore F, Lecleire S, Pop D, et al. Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer. Am J Gastroenterol 2007;102:2557-63. https://doi.org/10.1111/j.1572-0241.2007.01437.x
  18. Park JW, Kim JH, Choi EK, et al. Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2011;81:691-7. https://doi.org/10.1016/j.ijrobp.2010.06.041
  19. Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med 2007;48 Suppl 1:78S-88S.
  20. Chen SH, Chan SC, Chao YK, Yen TC. Detection of synchronous cancers by fluorodeoxyglucose positron emission tomography/computed tomography during primary staging workup for esophageal squamous cell carcinoma in Taiwan. PLoS One 2013;8:e82812. https://doi.org/10.1371/journal.pone.0082812
  21. Hanamoto A, Takenaka Y, Shimosegawa E, et al. Limitation of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography (FDG-PET) to detect early synchronous primary cancers in patients with untreated head and neck squamous cell cancer. Ann Nucl Med 2013;27:880-5. https://doi.org/10.1007/s12149-013-0765-x
  22. Malik V, Johnston C, Donohoe C, et al. (18)F-FDG PET-detected synchronous primary neoplasms in the staging of esophageal cancer: incidence, cost, and impact on management. Clin Nucl Med 2012;37:1152-8. https://doi.org/10.1097/RLU.0b013e31827083ba
  23. Strobel K, Haerle SK, Stoeckli SJ, et al. Head and neck squamous cell carcinoma (HNSCC): detection of synchronous primaries with (18)F-FDG-PET/CT. Eur J Nucl Med Mol Imaging 2009;36:919-27. https://doi.org/10.1007/s00259-009-1064-6
  24. van Westreenen HL, Westerterp M, Jager PL, et al. Synchronous primary neoplasms detected on 18F-FDG PET in staging of patients with esophageal cancer. J Nucl Med 2005;46:1321-5.

Cited by

  1. Immunotherapy for Esophageal Squamous Cell Carcinoma vol.19, pp.5, 2015, https://doi.org/10.1007/s11912-017-0590-9
  2. Early detection of esophageal second primary tumors using Lugol chromoendoscopy in patients with head and neck cancer: A systematic review and meta‐analysis vol.41, pp.4, 2015, https://doi.org/10.1002/hed.25548
  3. A retrospective analysis of the treatment results for advanced synchronous head and neck and esophageal cancer vol.1, pp.1, 2015, https://doi.org/10.1259/bjro.20190015
  4. Endoscopic submucosal dissection for the treatment of synchronous hypopharyngeal mass and esophageal superficial carcinoma vol.38, pp.6, 2015, https://doi.org/10.1007/s12664-019-00984-1
  5. Clonal relationship of synchronous head and neck cancer and esophageal cancer assessed by single nucleotide polymorphism-based loss of heterozygosity analysis vol.19, pp.1, 2015, https://doi.org/10.1186/s12885-019-6394-6
  6. Immunotherapy for Esophageal Cancers: What Is Practice Changing in 2021? vol.13, pp.18, 2015, https://doi.org/10.3390/cancers13184632